Author Archives: Jillian Willard

Sanofi Pays ImmunoGen $30 Million in an Amended License Agreement

By | May 31, 2017

ImmunGen, which develops antibody-drug conjugates (ADCs) for the treatment of cancer, announced that it has amended its license agreements with Sanofi covering all compounds in development by Sanofi using ImmunoGen’s technology. Under the terms of the amended 2003 collaboration and license agreement, ImmunoGen has granted Sanofi a fully-paid, exclusive license to develop, manufacture, and commercialize… Read More »

Pfizer’s Epogen/Procrit Biosimilar gets FDA Advisory committee green light

By | May 26, 2017

Pfizer announced the FDA Oncologic Drugs Advisory Committee recommended approval of the Company’s proposed Epogen (Amgen) / Procrit (Johnson and Johnson) biosimilar across all indications. This is the first epoetin alfa biosimilar that has been recommended for approval by a U.S. FDA Advisory Committee. The product indications include treatment of anemia due to Chronic Kidney… Read More »

Thermo Fisher Scientific to Acquire CMO Patheon

By | May 18, 2017

The boards of directors at Thermo Fisher Scientific and Patheon have approved Thermo Fisher’s acquisition of Patheon for $35.00 per share in cash. The transaction represents a purchase price of approximately $7.2 billion, which includes the assumption of approximately $2.0 billion of net debt. Patheon provides contract development and manufacturing services, primarily at facilities in… Read More »

First New Treatment for ALS in More Than 20 Years Approved by FDA

By | May 11, 2017

MT Pharma America announced that the FDA has granted approval of Radicava (edaravone) to treat amyotrophic lateral sclerosis (ALS). ALS is a rapidly progressive neurodegenerative disease – the majority of patients die within two to five years of diagnosis. An estimated 6,000 Americans are diagnosed each year with ALS, an incurable disease that affects the… Read More »

Sanofi and Lonza Partner to Build Biologics Production Facility in Switzerland

By | April 28, 2017

Lonza has announced that they will partner with Sanofi to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland. The initial investment will be around CHF 290 million (€ 270 million), to be split equally between the companies. The initial phase of the facility will commence construction in… Read More »

Single Use Manufacturing & the Impact on Process, Facility Design & Procurement

By | April 3, 2017

Single use technology opens up a world of possibilities never considered before for biotech/pharma manufacturing but also brings with it a host of new challenges. As companies move from simple application of single use systems like bags (for buffer storage) to more complex single use systems and even entire single use facilities, the potential impact… Read More »

Massachusetts Joins Institute for Innovation in Biopharm Manufacturing

By | February 21, 2017

Massachusetts will be a partner in the nation’s first manufacturing innovation institute in biopharmaceutical manufacturing. The $250 million biopharmaceutical innovation institute is a national, public-private partnership, with federal matching funds provided by the US Department of Commerce’s National Institute of Standards and Technology. Massachusetts will anchor the northeastern node for the institute, which will be… Read More »

Broad Institute CRISPR Patents Upheld

By | February 16, 2017

Broad Institute has announced that the patents granted to MIT, Harvard and Broad Institute concerning CRISPR editing of eukaryotic genomes do not interfere with patent claims filed by UC Berkeley and the University of Vienna, according to a decision handed down by the U.S. Patent Trial and Appeal Board on February 15. The decision confirms… Read More »